Type 1 diabetes is a complex illness that has a significant impact on each patient’s health and well-being. Despite its severity, it often goes undiagnosed until patients are hospitalized with serious complications. In the last decade, new screening programs have made it possible to screen and identify children who may be at risk for type 1 diabetes before symptoms develop, allowing for earlier detection, management, and possible treatment to delay its onset. However, these screenings have only been used in limited settings, and few providers are equipped to offer the screening or follow-up care.
Ariadne Labs is forming a coalition to develop tools and resources to help pediatric clinicians in diverse clinical settings bring this care to their patients. We will work with key stakeholders, including clinicians, researchers, policy makers, payers, health care administrators, and caregivers, to design a work flow clinicians can use to support screening in their practice. We will then develop a plan to test the model in clinical settings and create an implementation plan to enable equitable access to screening throughout the U.S.